Researchers find that a drug sometimes used to treat multiple sclerosis triggers cell death in mesothelioma tumors.
Raleigh, NC (PRWEB) April 10, 2017
Cancer researchers in Hawaii now believe that FTY720, a drug derived from part of a fungus, has promise as a mesothelioma treatment, The results of their newly published study are the subject of an article on the Surviving Mesothelioma website. Click here to read the details.
The study conducted at the University of Hawaii Cancer Center suggests that FTY720 can trigger apoptosis or programmed cell death by blocking a signalling protein that is overexpressed in mesothelioma tumors.
"Our preclinical data indicate that FTY720 is a potentially promising therapeutic agent for malignant mesothelioma treatment.," writes study author Agata Szymiczek, a University of Hawaii Cancer Center molecular biology research specialist.
In a report in the Journal of Translational Medicine, the researchers say FTY720 also effectively reduced the size of mesothelioma tumors in lab mice without any serious toxicity.
"The fact that FTY720 was able to shrink mesothelioma tumors without toxic side effects in this preclinical study is a hopeful sign, especially given the potential complications associated with other types of mesothelioma treatments," says Alex Strauss, Managing Editor for Surviving Mesothelioma.
For more information about FTY720 and the new mesothelioma study, see MS Drug May Help Treat Malignant Mesothelioma, Too, now available on the Surviving Mesothelioma website.
Szymiczek, A, et al, "FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model", March 2017, Journal of Translational Medicine, https://www.ncbi.nlm.nih.gov/pubmed/28298211
For more than a decade, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.
For the original version on PRWeb visit: http://www.prweb.com/releases/2017/04/prweb14228989.htm
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.